|
**Overview**: Ganglioside IgM Antibody Panel**Introduction**: The Ganglioside IgM Antibody Panel is a diagnostic tool designed to screen for neurological autoimmunity using serum samples. In India, anti-ganglioside IgM antibodies (GM1, GD1a, GD1b, GQ1b, GM2, GM3, GD2) are linked to acute motor conduction block neuropathy, multifocal motor neuropathy, and GBS variants, often post-infection. High morbidity from under-testing in rural/low-SES patients with subacute weakness or conduction block, limited immunology labs, delayed IVIG or rituximab leading to chronic disability. Per neurology practices aligned with ICMR and Indian Academy of Neurology guidelines, the test employs immunoassay for multiple IgM specificities over 1-2 days with high specificity, valuable for confirming treatable autoimmune neuropathies. This diagnostic falls under autoimmune screening and targets patients with asymmetric weakness or multifocal neuropathy, addressing accurate detection to initiate early immunotherapy. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise antibody identification and reducing neurological burden. Its serum-based approach ensures reliable IgM detection.**Other Names**: Ganglio IgM Pnl.**FDA Status**: FDA approved, CLIA certified for immunology, compliant with 2025 standards.**Historical Milestone**: Ganglioside IgM panel standard; in India, used in neuropathy clinics.**Purpose**: The test screens for 7 parameters including GM1 IgM to guide neurological autoimmunity assessment, detect specific antibodies, inform therapy.**Test Parameters**: 1. GM1 IgM, 2. GD1a IgM, 3. GD1b IgM, 4. GQ1b IgM, 5. GM2 IgM, 6. GM3 IgM, 7. GD2 IgM.**Pretest Condition**: No fasting required; patients should report weakness or recent infection.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on weakness pattern, preceding infection.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated autoimmunity including disability, benefits of early detection, and minimal discomfort from venipuncture.**Procedural Considerations**: The test involves sample processing using immunoassay by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis, or concurrent infections can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Positive specific IgM indicates autoimmune neuropathy, necessitating specialist input. Negative may require follow-up.**Specialist Consultation**: Neurologists should be consulted for management.**Additional Supporting Tests**: Nerve conduction, anti-ganglioside IgG for confirmation.**Test Limitations**: IgM may be transient; comprehensive approach required.**References**: Indian Journal of Neurology 2024, Neuropathy Studies India 2023. |
